Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by scarlet1967on Dec 18, 2020 4:54pm
241 Views
Post# 32142550

RE:RE:CIDY vs THTX..

RE:RE:CIDY vs THTX..Well THTX apparently doesn't want to be CYDY.
As a shareholder of Theratechnologies for almost a decade one has to be extremely thick skinned to stay loyal to this company. So why not try to return the favour by being shareholder friendly? why the valuation is nothing close to comparable companies?
It is about lack of credibility and past failures that's why I believe not announcing the submission of a well overdo protocol is strategically an epic fail, the market doesn't ascribe any credit to their programs rightfully cause they missed the deadline and not even want to elaborate exactly why apart from "additional insights" etc etc and now not even announcing the submission of a protocol which is struggling to convince it's validity.
Paul sounded very confident in the last conference so why not follow that through instead of sending mixed signals by all that secrecy.
CYDY might be too promotional but look how they managed to convince the market, what is wrong with that, for instance they let individual shareholders submit questions! to me one can not be more transparent and that's why the market believe them the total opposite situation to THTX.
Paul needs to set things straight....


<< Previous
Bullboard Posts
Next >>